Introduction
============

The successes of combination antiretroviral therapy (cART) have substantially increased life expectancy in persons with HIV (PWH) who can now expect to live a relatively normal lifespan ([@fcaa015-B50]). Despite these successes, the impact of ageing in PWH is now a topic of major concern, as these individuals may have heightened susceptibility to co-morbidities associated with ageing ([@fcaa015-B48]). Indeed, age-related co-morbidities appear to affect younger PWH more frequently than those who seroconvert at an older age ([@fcaa015-B30]). These and other findings ([@fcaa015-B28]) have given rise to hypotheses of premature or accelerated ageing with chronic HIV disease.

Recent research focusing on ageing in HIV has aimed to find biomarkers of accelerated ageing in the brain and/or periphery that can quantify the unique ageing process in PWH ([@fcaa015-B45]). Among these studies, neuroimaging investigations of HIV are becoming more sophisticated, with structural and functional alterations linked to HIV infection and ageing ([@fcaa015-B13]). Early structural MRI studies of PWH naïve to treatment showed brain atrophy indicative of accelerated ageing ([@fcaa015-B16]; [@fcaa015-B68]), and more recent studies in the cART era have tended to support this ([@fcaa015-B35]; [@fcaa015-B31]). Conversely, other neuroimaging studies have shown independent effects of HIV and ageing on brain volume ([@fcaa015-B2]), as well as on cerebral blood flow and brain activation (fMRI; [@fcaa015-B3]). In this context, magnetoencephalography (MEG) functional imaging is a particularly novel and promising technique for identifying biomarkers of HIV and neural ageing ([@fcaa015-B65]). However, despite multiple MEG studies showing HIV-related changes in neural function and dynamics ([@fcaa015-B63], [@fcaa015-B66]; [@fcaa015-B60]), no studies have examined ageing in HIV.

Another major question surrounds the relationship between premature ageing and incidence of HIV-associated neurocognitive disorder (HAND). HAND is thought to be linked with neuroimmune-related inflammation ([@fcaa015-B27]) and while cART has sharply reduced the most severe forms of HAND (i.e., HIV-associated dementia), milder forms remain quite common with estimates ranging from 35% to 70% of all PWH ([@fcaa015-B53]; [@fcaa015-B33]; [@fcaa015-B67]; [@fcaa015-B49]). Previous studies have linked accelerated ageing and HAND ([@fcaa015-B37]; [@fcaa015-B52]), but the relationship between brain ageing and HAND has yet to be fully understood, and the impact of the many other factors at play (e.g. drug misuse and cART neurotoxicity) also needs further study.

In the current study, we aimed to investigate interactions between ageing and HIV-infection on the neural oscillations that serve visual attention function. We hypothesized that selective attention functioning in PWH would follow a differential trajectory of age-related change as compared to adults without HIV. Our overall objective was to examine these differences in the context of neural oscillations and to identify how ageing-related alterations in neural activity were associated with neuropsychological performance and HIV-related clinical measures.

Materials and methods
=====================

Participant recruitment
-----------------------

Adults with HIV were recruited from the HIV Clinic of the University of Nebraska Medical Center and demographically matched uninfected control participants were recruited from the local community. To optimize the study of ageing, participants were recruited to create an even distribution across age, ranging from 22 to 72 years. For the HIV-infected groups, inclusion criteria included receiving effective cART and having an undetectable viral load within 3 months of participation in the study, defined as \<50 copies/ml. Uninfected controls were recruited to match HIV-infected participants based on their ethnicity, age, sex and handedness. Exclusion criteria included any chronic medical illness affecting CNS function (other than HIV-infection/HAND), any neurological or psychiatric disorder (other than HAND), acute intercurrent illness, pregnancy, history of head trauma, current substance use disorder and presence of any ferrous metal implant, including orthodonture, which may interfere with the MEG data acquisition and/or be an MRI safety concern. For this study, additional exclusions of active drug use or alcohol abuse, moderate-to-severe depressive symptoms on the Beck Depression Inventory ([@fcaa015-B9]) and incomplete or artefactual MEG data were implemented as outlined in [Fig. 1](#fcaa015-F1){ref-type="fig"}. The Institutional Review Board at the University of Nebraska Medical Center approved this protocol. Each participant provided written informed consent, and all participants completed the same protocol.

![**Participant disposition**. In total, 133 controls and 121 PWH were enrolled. Participants were excluded for current drug use and moderate-to-severe depressive symptoms. Control participants who were found to be cognitively impaired were also excluded. Finally, participants were excluded due to missing or artefactual MEG data, or poor MEG task performance. The final sample included 92 unimpaired controls, 46 unimpaired PWH and 27 participants with HAND.](fcaa015f1){#fcaa015-F1}

Neuropsychological battery
--------------------------

This study followed the same protocol as described in [@fcaa015-B38]. Participants completed a neuropsychological battery assessing multiple functional domains, including attention \[WAIS-III Symbol Search ([@fcaa015-B59]) and Stroop Word ([@fcaa015-B21])\], speed of processing \[Trail Making Part A ([@fcaa015-B32]), WAIS-III Digit Symbol, and Stroop color\], executive functioning \[Trail Making Part B, Stroop interference, phonemic verbal fluency and semantic verbal fluency ([@fcaa015-B32])\], fine motor \[grooved pegboard ([@fcaa015-B36]; [@fcaa015-B32])\], verbal learning and memory \[Hopkins Verbal Learning Test--Revised ([@fcaa015-B12])\] and language \[Wide Range Achievement Test-4^th^ edition ([@fcaa015-B61]), Word Reading subtest\]. Composite scores for each domain were computed by calculating demographically normalized z-scores and taking an average of the z-scores for all tests within that domain. Along with an assessment of activities of daily living, these scores were used to diagnose HAND according to the Frascati guidelines ([@fcaa015-B4]). Analyses utilized a full composite score, which represented an average of all neuropsychological composite scores across domains.

MEG acquisition and selective attention task
--------------------------------------------

To examine selective attention and susceptibility to interference, participants completed an arrow-based Eriksen flanker task while undergoing MEG ([@fcaa015-B24]). Briefly, participants performed 200 trials of the task, each beginning with a fixation that was presented for 1.45--1.55 s, followed by a row of five arrows for 2.50 s. Participants responded with their right hand whether the middle arrow was pointing to the left (index finger) or right (middle finger), and trials were considered congruent when the middle arrow was in the same direction as the flanking arrows, and incongruent when the middle arrow was in the opposite direction. Participants completed the task in a non-magnetic chair in a one-layer magnetically shielded room with active shielding engaged to compensate for environmental noise. Throughout the task, MEG data were collected continuously at 1 kHz with an acquisition bandwidth of 0.1--330 Hz using a 306-sensor Elekta system (Helsinki, Finland). Further details about the flanker task and MEG data acquisition can be found in [@fcaa015-B43].

MEG preprocessing, time--frequency transformation and sensor-level statistics
-----------------------------------------------------------------------------

MEG data preprocessing used Brain Electrical Source Analysis software (BESA version 6.1; BESA GmbH, Gräfelfing, Germany) and followed previously published methods described in [@fcaa015-B43]. Briefly, each participant's data were individually corrected for head movement and subjected to noise reduction using the temporally extended signal space separation method ([@fcaa015-B55]). Cardiac and blink artefacts were corrected using signal-space projection (SSP; [@fcaa015-B56]). MEG data were then divided into epochs of 2.00 s duration (−500 to 1500 ms), with 0.0 s defined as stimulus onset and the baseline defined as the −450 to −50 ms time window. Noisy and high-amplitude trials were rejected based on a participant-specific fixed threshold method as described in [@fcaa015-B46]. After artefact rejection, an average of 82.69 trials in the congruent and 81.96 trials in the incongruent condition remained in each participant; and the difference in number of accepted trials did not differ between condition (*t*(165)=1.32, *P *\>* *0.10), nor between groups (*F*(2,163)=2.11, *P \> *0.10).

Artefact-free epochs were transformed into the time--frequency domain using complex demodulation at a 1.0 Hz, 50 ms resolution. Specific time--frequency windows of interest were determined by statistical analysis of the sensor-level spectrograms across all correct trials (congruent and incongruent) for each gradiometer in the array. Each data point in the spectrogram was initially evaluated using a mass univariate approach based on the general linear model. To reduce the risk of false-positive results while maintaining reasonable sensitivity, a two-stage procedure was followed to control for Type 1 error. In the first stage, paired-sample *t*-tests comparing each data point to its spectrally respective baseline were conducted and the output spectrogram of *t*-values was thresholded at *P* \< 0.05 to define time--frequency bins containing potentially significant oscillatory deviations across all participants. In Stage 2, time--frequency bins that survived this threshold were clustered with temporally and/or spectrally neighbouring bins that were also significant, and a cluster value was derived by summing all of the *t*-values of all data points in the cluster. Non-parametric permutation testing was then used to derive a distribution of cluster values and the significance level of the observed clusters (from stage one) was tested directly using this distribution ([@fcaa015-B25]; [@fcaa015-B42]). For each comparison, at least 10 000 permutations were computed to build a distribution of cluster values. Based on these analyses, the time--frequency windows containing significant oscillatory events across all participants and conditions were selected for imaging.

MEG source imaging
------------------

Structural T1-weighted MRI images were acquired with a Philips Achieva 3 T X-series scanner using an eight-channel head coil and a 3D fast field echo sequence with the following parameters: TR: 8.09 ms; TE: 3.7 ms; field of view: 24 cm; matrix: 256 × 256; slice thickness: 1 mm with no gap; in-plane resolution: 0.9375 ×  0.9375 mm; sense factor: 1.5. Each participant's MEG data were then coregistered with their individual structural T1-weighted MRI data. For the few participants that did not complete an MRI (3% of participants), a template MRI was used. For each statistically determined time--frequency window, the underlying cortical activity was imaged using a reference-free dynamic imaging of coherent sources beamformer ([@fcaa015-B57]; [@fcaa015-B29]). This approach derives the local power in voxel space by utilizing Fourier-transformed data to calculate the cross-spectral densities of all combinations of MEG gradiometers averaged over the time--frequency range of interest. For the forward solution, we employed a spherical head model and a 4.0 × 4.0 × 4.0 mm voxel space grid with two orientations per voxel. Effectively, the beamformer operator generates a spatial filter for each grid point, which passes signals without attenuation from a given neural region while minimizing interference from activity in all other brain areas. The properties of these filters are determined from the MEG covariance matrix and the forward solution for each grid point in the image space, which are used to allocate sensitivity weights to each sensor in the array for each voxel in the brain. The individual images were normalized using a separately averaged pre-stimulus noise period of equal duration and bandwidth ([@fcaa015-B34]). Separate images were computed for each condition per time--frequency window in order to optimize the beamformer weighting vectors for each condition ([@fcaa015-B7]), and to test for conditional differences. All beamformer images were visually inspected individually for significant outliers, and such images were excluded from whole-brain statistics. We also conducted a *post hoc* analysis to understand the impact, if any, of these exclusions on the final results.

Statistical analysis
--------------------

The goal of the study was to determine the interactions between age and HIV on selective attention function, both behaviourally and in the brain. Due to the size of the HAND group in comparison to the control group, all primary analyses focused on the comparison between controls and PWH, regardless of HAND status. *Post hoc* analyses were then used to examine whether group differences were independent of, or driven by, neuropsychological impairment. Mixed-model ANCOVA was used to examine reaction time on the task, using condition (congruent versus incongruent) as a within-participants factor, HIV status as a between-participants factor and age as a covariate of interest. The HIV-by-age interaction term was included to examine the interactive effect of HIV and age, and this term was excluded to probe the lower order interactions (condition-by-HIV and condition-by-age). Additionally, to determine the effect of HAND, we re-ran the analyses after breaking up the HIV group into unimpaired PWH and those with HAND.

To statistically determine the interaction between age and HIV on neural activity, we performed whole-brain ANCOVAs. We first subtracted each participant's congruent image from their incongruent image to obtain flanker 'interference maps'. Statistics on these images effectively test for the condition interaction (i.e. susceptibility to interference) with the variable of interest. We then ran whole-brain ANCOVAs using HIV and age as factors of interest. Finally, a *P* \< 0.001 and *k* threshold of 200 voxels was applied to the resulting map representing the interaction between age and HIV on flanker interference. For each significant cluster, the voxel with the highest *F*-value was used for regression with clinical metrics.

Effects of HIV-related clinical measures
----------------------------------------

We also aimed to examine whether our neural findings could be explained by HIV-related clinical measures. These analyses focused exclusively on the PWH. Specifically, we used measures of global neuropsychological performance, duration of HIV infection, current CD4 count, CD4 nadir and current efavirenz-based antiretroviral therapy. We focused on efavirenz because it is known to have CNS-related side effects ([@fcaa015-B1]). To examine this, we created a categorical variable comparing participants who were currently receiving efavirenz-based cART to those on non-efavirenz regimens. To determine the effects of global neuropsychological performance, we computed an average of the composite scores used to diagnose HAND (see section 'Neuropsychological battery'). We also performed follow-up analyses separating neuropsychological performance by cognitive domain. For duration of HIV infection, we used a self-report measurement of time since diagnosis in years. We then ran univariate ANCOVAs with age, global neuropsychological performance, duration of HIV infection, current CD4 count, CD4 nadir and current efavirenz antiretroviral therapy as independent predictors, and reaction time interference (in milliseconds) and neural interference activity (peak voxel amplitude in pseudo-*t*'s) as dependent variables.

Surface-based morphometry
-------------------------

Finally, a follow-up exploratory analysis was performed to examine the cortical thickness in brain regions identified through the MEG analyses as displaying differential HIV-by-age effects. Participants' high-resolution T1-weighted MRI data were processed using the standard surface-based morphometry pipeline in the CAT12 toolbox (<http://dbm.neuro.uni-jena.de/cat/>, v12.6, 25 February 2020, date last accessed) at a resolution of 1 mm^3^ within SPM12. This method utilizes a projection-based thickness approach to estimate cortical thickness and reconstruct the central surface in one step ([@fcaa015-B23]). Briefly, following tissue segmentation ([@fcaa015-B6]) the white matter (WM) distance is estimated, and the local maxima are projected onto other grey matter voxels using a neighbouring relationship described by the WM distance. This method accounts for partial volume correction, sulcal blurring and sulcal asymmetries. Topological defects are corrected based on spherical harmonics ([@fcaa015-B69]), and the cortical surface mesh was re-parameterized into a common coordinate system via an algorithm that reduces area distortion ([@fcaa015-B70]). Finally, the resulting maps were resampled and smoothed using a 15 mm FWHM Gaussian kernel.

Regions of interest (ROIs) were then created by using the peak voxel coordinates identified from the HIV-by-age maps. Specifically, we used the WFU Pickatlas (v3.0; [@fcaa015-B41]; [@fcaa015-B40]). to generate a 10 mm sphere centred on each peak voxel coordinate identified from MEG interaction maps. These normalized volume masks were transformed into surface template space using the transform provided in CAT12. Cortical thickness values were then extracted per participant by computing the average thickness within each ROI mask. Thus, the values reflected the average cortical thickness within the oscillatory response-based ROI (i.e. the cortical tissue displaying a significant HIV-by-age interaction). Statistical comparisons were then made based on the previous statistical models, using cortical thickness in the ROIs as dependent variables. That is, we ran ANCOVAs with HIV and age as factors of interest, interrogating both the HIV-by-age interaction and the independent main effects.

Data availability
-----------------

The data that support the findings of this study are available from the corresponding author (T.W.W.), upon reasonable request.

Results
=======

Participant demographics and clinical measures
----------------------------------------------

In total, 121 PWH and 133 uninfected controls, aged 22--72 years, were recruited for the study. Of the 121 PWH, 45 were found to have HAND. We excluded 18 controls and 26 PWH who reported current drug use, most of whom reported cannabis use. Additionally, we excluded one control participant and seven PWH who had a score indicating moderate-to-severe depressive symptoms on the Beck Depression Inventory ([@fcaa015-B8]). Of note, eight PWH who were excluded for drug use also had moderate-to-severe depressive symptoms. Finally, we excluded 12 controls who were found to be cognitively impaired on neuropsychological testing. With respect to data acquisition and task performance, 10 controls, 8 unimpaired PWH and 7 participants with HAND were excluded for missing MEG data, artefactual MEG data (e.g. due to dental work), and/or poor task performance during MEG (i.e. \<50% accuracy on either condition). Finally, one participant had a viral load of 54 copies/ml and was still included in the analysis. Ultimately, 92 unimpaired controls and 73 PWH, 27 of whom had HAND ([Fig. 1](#fcaa015-F1){ref-type="fig"}) were included in the final sample. Of the participants with HAND, 19 met diagnostic criteria for asymptomatic neurocognitive impairment, 6 for mild neurocognitive disorder, and 2 met criteria for HIV-associated dementia. Group demographics for the final sample are reported in [Table 1](#fcaa015-T1){ref-type="table"}. The groups ranged in age from 22 to 72 years, with each group closely matched in age and sex (see [Table 1](#fcaa015-T1){ref-type="table"}). PWH had a median CD4 of 678 cells/mm^3^ (range: 102--2617) at the time of enrollment. Median CD4 nadir for all PWH was 232 cells/mm^3^ (range: 3--586), and neither current CD4 nor CD4 nadir differed as a function of HAND status (*P* \> 0.10).

###### 

Group demographics

                                               Controls       Unimpaired HIV    HAND              *P*-value
  -------------------------------------------- -------------- ----------------- ----------------- -----------
  Age (years)                                  45.7 (15.7)    47.6 (12.0)       47.5(13.8)        \>0.05
  Sex (F/M)                                    41/51          19/27             11/16             \>0.05
  Race (Caucasian/African American/Other)      66/22/4        34/11/2           15/12/0           \>0.05
  Average total neuropsychological *z*-score   0.04 (0.53)    0.01 (0.40)       −0.94 (0.34)      \<0.001
  Congruent accuracy (%)                       98.06 (0.04)   98.72 (0.03)      96.70 (0.07)      \>0.05
  Incongruent accuracy (%)                     98.04 (0.04)   97.98 (0.04)      92.11 (0.14)      \<0.001
  CD4 nadir in cells/mm^3^ (median; range)     --             227 (3--586)      237 (14--469)     \>0.05
  Current CD4 (median; range)                  --             684 (167--2617)   624 (102--1512)   \>0.05
  Efavirenz-based therapy (\# participants)    --             21                10                --

Values are represented as means (SD).

Behavioural selective attention deficits
----------------------------------------

An ANCOVA comparing controls to PWH indicated a significant three-way interaction of condition-by-HIV-by-age on reaction time (*F*(1,161) = 6.16; *P* = 0.014; *η*^2^ = 0.037; [Fig. 2](#fcaa015-F2){ref-type="fig"}). Probing this interaction revealed a significant condition-by-group interaction such that PWH had larger flanker effects (i.e. greater susceptibility to interference; *F*(1,162) = 7.12; *P* = 0.008; *η*^2^ = 0.042). Additionally, controls showed a significant condition-by-age interaction such that older age was associated with greater susceptibility to interference (*F*(1,90) = 9.99; *P* = 0.002; *η*^2^ = 0.100). This association with age was not present in PWH (*P* \> 0.10). Simple main effects of condition, group and age were all significant such that the incongruent condition, HIV and older age were associated with longer reaction times (all *P*s \< 0.005). Notably, the three-way interaction was also significant when splitting the HIV group by HAND status, creating three subject groups (*F*(2,159) = 3.944; *P* = 0.043; *η*^2^ = 0.039). The condition-by-group interaction additionally remained significant such that the HAND participants were the most susceptible to interference (*F*(1,161) = 6.63; *P* = 0.002; *η*^2^ = 0.076). Pairwise comparisons of the three groups adjusting for age showed a significant difference between the control and HAND groups (*P* \< 0.001), and between the unimpaired HIV and HAND groups (*P* = 0.017). The difference between the control and unimpaired PWH groups was trending (*P* = 0.082). Lastly, it should be noted that one participant with HAND had an outlier interference effect (431.61 ms). This participant's data is not displayed in [Fig. 2C](#fcaa015-F2){ref-type="fig"}, but it was included in the analysis, and inclusion/exclusion of the participant's data did not affect the significance of the results.

![**Behavioural performance**. (**A**) Mean reaction time per condition and group is shown, with error bars reflecting the SEM. (**B**) The interference effect (incongruent--congruent condition) is shown for each group. (**C**) The susceptibility to interference effect (incongruent minus congruent) is plotted against age for the three groups. Mixed-model ANCOVA revealed a significant condition-by-HIV-by-age interaction and this interaction remained significant when splitting the HIV group by HAND status. For the control group, older age was associated with significantly greater susceptibility to interference. This association was not seen in the HIV group. Instead, the HIV-infected group showed a larger interference effect irrespective of age, largely driven by HAND participants (see **A** and **B**). Overall, this indicates that increased age is associated with increased susceptibility to interference, and that participants with HIV exhibit this effect irrespective of ageing.](fcaa015f2){#fcaa015-F2}

Susceptibility to interference shows theta-specific HIV-by-age interaction
--------------------------------------------------------------------------

MEG sensor-level statistics comparing the active and baseline time--frequency windows indicated two distinct spectral windows; one in the theta range (3--6 Hz), and one in the alpha range (8--12 Hz). Briefly, a strong and transient theta synchronization was present from 0 to 350 ms, and a large alpha desynchronization was present from 250 to 700 ms (both cluster *P* \< 0.001). These two spectro-temporal windows were used for image reconstruction, with respective baseline periods of equal bandwidth and duration (theta: −400 to −50ms; Alpha: −500ms to −50ms). Images were calculated for congruent and incongruent conditions separately and, to examine interference effects, congruent images were subtracted from incongruent images to generate maps of flanker interference activity.

Whole-brain ANCOVAs examining the interaction between HIV and ageing on flanker interference activity were then calculated. With regard to alpha activity, there were no significant HIV-by-age interaction effects. In contrast, for theta, significant interactions were found in the right prefrontal cortex and the left posterior parietal cortex ([Fig. 3](#fcaa015-F3){ref-type="fig"}; *P* \< 0.001, corrected). Visualizing these interactions showed that, in the frontal cortex, control participants had a positive relationship between age and interference activity, while PWH had a negative relationship between age and susceptibility to interference ([Fig. 3A](#fcaa015-F3){ref-type="fig"}). In the posterior parietal cortex, controls exhibited no relationship between age and interference activity, while PWH had a positive relationship ([Fig. 3B](#fcaa015-F3){ref-type="fig"}). That is, in the parietal cortex, older PWH showed increasing theta activity with increasing susceptibility to interference. When including all beamformer images regardless of artefacts, similar significant clusters in the prefrontal cortex and posterior parietal cortex were still present. The peak voxels in these statistical interaction maps were then used in correlational analyses between theta interference activity and reaction time interference, but these did not reveal any significant relationships (both *P'*s \> 0.10). Additionally, probing the main effects of the theta interference ANCOVA showed a significant effect of HIV in the right inferior parietal cortex, above and beyond age and the HIV-by-age interactive term ([Fig. 4](#fcaa015-F4){ref-type="fig"}). Finally, the main effect of age failed to show any significant clusters.

![**Whole-brain ANCOVAs of theta interference activity.** Flanker interference maps were created by subtracting congruent images from incongruent images. These were then subjected to a univariate ANCOVA, and the resulting HIV-by-age interaction contrasts are displayed. Colour bars to the left of each brain image indicate the t-statistic for the age-by-HIV interaction, with warm colours indicating a positive difference between controls and PWH in the age-by-neural activity slope, and cool colours indicating a negative difference. Differences in theta activity were found in the right prefrontal cortex (**A**) and the left posterior parietal cortex (**B**). To visualize these interactions, the peak voxel of each cluster was used to extract the flanker interference values for each participant. Interference activity from the prefrontal peak voxel (**A**) and parietal peak voxel (**B**) was then plotted against age for each group, with HAND participants included in the HIV group, but denoted with yellow triangles (versus yellow squares for unimpaired PWH). Ultimately, in these regions, the relationship between age and flanker interference activity differed as a function of HIV infection.](fcaa015f3){#fcaa015-F3}

![**Main effect of HIV on theta interference activity.** The theta interference univariate ANCOVA showed a main effect of HIV in the right inferior parietal cortex. The statistical map displaying the main effect of HIV, above and beyond the effects of ageing and their interaction, is displayed with the colour scale bar indicating the *t*-statistic. The peak voxel of the cluster was used to extract the flanker interference values for each participant, and the estimated marginal means for the effect of HIV were then plotted. These values represent the group-wise theta interference activity adjusted for the effect of ageing and the HIV-by-age interaction term. The error bars reflect +/− one SEM.](fcaa015f4){#fcaa015-F4}

Neuropsychological performance associated with behavioural performance
----------------------------------------------------------------------

Next, we focused on PWH and examined a number of clinical measures. Of note, five PWH did not have current CD4 data, and one participant did not have CD4 nadir data. Additionally, we performed a square root transformation of the current CD4 values to normalize the distribution of data. All other covariates showed normal distributions. An ANCOVA of reaction time interference on age, global neuropsychological performance, duration of HIV infection, current CD4 count, CD4 nadir and current efavirenz-based antiretroviral therapy showed a significant effect of neuropsychological performance above and beyond all other variables (*F*(1,60)=13.53; *P* \< 0.001; *η*^2^ = 0.184), such that poorer global neuropsychological performance was associated with greater behavioural susceptibility to interference. Global neuropsychological performance was the only predictor that was significantly associated with reaction time interference after controlling for all other variables in the model. Notably, global neuropsychological performance was not significantly correlated with any of the clinical measures, including CD4 counts and current efavirenz therapy (all *P* \> 0.05). When splitting the global neuropsychological performance variable into its domains and re-running the model, the attention domain was the only domain with a significant effect above and beyond all other variables (*P* \< 0.05).

HIV clinical measures associated with parietal theta activity, but not prefrontal activity
------------------------------------------------------------------------------------------

To understand the relationship between HIV clinical measures and our identified neural differences, we ran ANCOVA models using the same HIV clinical measures described above as independent variables, and using prefrontal and parietal theta interference activity as dependent variables. As before, these analyses included PWH only. An ANCOVA of theta interference activity in the right prefrontal cortex showed only a significant effect of age (*F*(1,46) = 4.69; *P* = 0.036; *η*^2^ = 0.092). In contrast, an ANCOVA of theta interference activity in the left posterior parietal cortex showed significant effects of age (*F*(1,46) =  13.18; *P* \< 0.001; *η*^2^ = 0.223), time since diagnosis (*F*(1,46) = 5.34; *P* = 0.025; *η*^2^ = 0.104), and current efavirenz-based therapy (*F*(1,46) = 8.87; *P* = 0.005; *η*^2^ = 0.162), each above and beyond all other predictors. The partial plots and marginal means displaying these significant effects show that older age, longer disease duration and current efavirenz therapy independently predict stronger parietal theta interference activity ([Fig. 5](#fcaa015-F5){ref-type="fig"}). All of these effects also remained significant when including the five individuals missing CD4 data (see above) by using the CD4 count on their medical record closest to their participation in the study. Additionally, these effects remained significant when splitting the global neuropsychology variable into its respective domains, ultimately showing that neither the global nor the individual neuropsychological domains was significant.

![**Partial plots of parietal theta interference activity on clinical measures.** ANCOVAs of theta activity within the posterior parietal cortex showed that time since diagnosis, age and current efavirenz therapy were significantly associated with interference activity. These predictors were independently significant above and beyond each other, CD4 measures and neuropsychological performance. (**A**) After accounting for other clinical measures, older age was associated with stronger theta interference activity in the parietal. The *Y*-axis shows parietal theta interference activity and the x-axis shows age in years. (**B**) Similarly, time since HIV diagnosis was associated with stronger parietal theta activity; *Y*-axis shows parietal theta interference activity and *X*-axis shows time since HIV diagnosis in years. Participants with HAND were included in these analyses and are shown using triangles. (**C**) Finally, adjusted marginal means for participants currently on cART regimens including efavirenz versus those on other cART regimens showed stronger parietal theta interference activity for those taking efavirenz. Measures in all three plots are shown controlling for all other predictors in the model, and were statistically independent of all other predictors.](fcaa015f5){#fcaa015-F5}

Independent effects of HIV and age on cortical thickness
--------------------------------------------------------

Cortical thickness was computed for all participants with T1 MRIs. ROIs were determined using the prefrontal and parietal peaks displaying significant HIV-by- age interaction effects ([Fig. 3](#fcaa015-F3){ref-type="fig"}). Notably, two participants (both PWH) were determined to have low-quality cortical thickness computations when examining sample homogeneity (as defined by \>3 SDs away from the mean in overall correlation with other volumes), and thus were excluded from further analyses. Average cortical thickness across the two ROIs ([Fig. 6](#fcaa015-F6){ref-type="fig"}) was determined for each participant and ANCOVAs were utilized to probe the HIV-by-age interaction. These models both failed to show an interaction effect of HIV by age (both *P*'s \> 0.10). ANCOVAs without the interactive term were then used to probe the main effects of age and HIV. A main effect of age above and beyond HIV was seen in both the prefrontal (*F*(1,155) = 49.66; *P* \< 0.001; *η*^2^ = 0.243) and parietal (*F*(1,155) = 8.27; *P* = 0.005; *η*^2^ = 0.051) regions such that increasing age was associated with decreased cortical thickness. Finally, a main effect of HIV above and beyond the effect of age was also found, such that PWH displayed cortical thinning in both prefrontal (*F*(1,155) = 5.37; *P* *=* 0.022; *η*^2^ = 0.033) and parietal (*F*(1,155) = 5.44; *P* = 0.021; *η*^2^ = 0.034) regions ([Fig. 6](#fcaa015-F6){ref-type="fig"}). Bivariate correlations of prefrontal and parietal cortical thickness with their respective theta interference activity did not show significant relationships (both *P'*s \> 0.10). When correlating with reaction time interference, decreased left parietal cortical thickness was significantly associated with increased reaction time interference (*r* = −0.163, *P* = 0.041), while prefrontal cortical thickness was not associated with reaction time interference (*P* \> 0.10).

![**Cortical thickness in prefrontal and parietal regions of interest**. Surface-constrained regions of interest were created using the peak voxels of the theta HIV-by-age interaction maps. These masks are displayed with (**A**) corresponding to the right prefrontal peak and (**B**) corresponding to the left parietal peak. The cortical thickness averaged across these ROIs were extracted for each participant, and ANCOVAs were utilized to determine the interaction between HIV and age on cortical thickness. Both regions failed to show an interactive effect of HIV-by-age (both *P'*s \> 0.10); however, both ANCOVAs without the interaction term showed main effects of age and HIV above and beyond one another (all *P's* \< 0.05).](fcaa015f6){#fcaa015-F6}

Discussion
==========

Our results indicated that selective attention deficits related to HIV infection differ as a function of ageing. Behaviourally, we found that selective attention performance decreases with older age in control participants, while in PWH selective attention was impaired regardless of age. This may be a sign of premature ageing, as younger PWH appeared to have selective attention abilities near those of much older controls. To examine the neural oscillatory dynamics that underlie this interaction, we ran whole-brain statistics for specific neural responses underlying selective attention processing. These analyses indicated that prefrontal and parietal theta activity had unique relationships with HIV and ageing. Such neural activity did not appear to be related to global neuropsychological performance, potentially showing a pathological ageing process that is independent of HAND. Instead, we found that parietal activity was associated with the duration of HIV infection and current efavirenz therapy. This study is the largest MEG and more broadly the largest functional brain imaging study ever conducted with PWH, and the critical implications for HIV, ageing and cognitive function are discussed at length below.

Our findings of behavioural selective attention deficits in HIV and HAND were consistent with previous literature showing such attention deficits, even in PWH with virologic suppression ([@fcaa015-B15]; [@fcaa015-B22]; [@fcaa015-B58]; [@fcaa015-B38]). Herein, we extended these findings by identifying how these selective attention deficits change with ageing. The significant association between age and susceptibility to interference in controls suggested that selective attention function normally decreases with age. However, in PWH, our data showed that selective attention deficits were present irrespective of age, which may support the notion of HIV-related premature ageing. In other words, HIV infection may have conferred a selective attention deficit that is normally seen with increasing age, supporting the theory that HIV infection causes premature ageing in the brain. Our data also unsurprisingly showed that global neuropsychological performance is associated with these deficits.

In regards to the MEG data, our findings expand on the growing body of MEG literature focusing on HIV, with HIV-specific differences seen in resting state ([@fcaa015-B10], [@fcaa015-B11]), somato-motor function ([@fcaa015-B63], [@fcaa015-B64]; [@fcaa015-B54]), visual processing ([@fcaa015-B62]), working memory ([@fcaa015-B66]) and attention ([@fcaa015-B38]; [@fcaa015-B60]). The current study expands the literature by focusing on ageing in HIV and utilizing a significantly larger sample than any of the previous MEG studies. Whole-brain statistics examining the age-by-HIV interaction revealed two significant clusters in the theta band, one in the right prefrontal cortex and the other in the left posterior parietal cortex. These regions are consistent with recent findings of cortical thickness reductions specifically in frontal and parietal areas in virally suppressed PWH ([@fcaa015-B51]). Indeed, we were able to replicate this HIV-related cortical thinning in our ROI analyses, but these structural changes did not show interactive effects with ageing. This lack of an HIV-by-age interaction is consistent with previous structural MRI studies ([@fcaa015-B20]), and may suggest the effect is more purely functional and/or increased sensitivity of task-based MEG towards such effects. In the left posterior parietal cortex, the interaction effect revealed that older PWH had increased theta activity with greater interference, while control participants showed no relationship between ageing and flanker interference theta activity. This HIV-specific increase in theta power with age may reflect a need for greater recruitment of the parietal cortex during selective attention in older PWH. As per the prefrontal theta activity, PWH had decreasing flanker interference activity with age, while older controls had increasing prefrontal theta activity with increasing age. Together, these data may indicate that, during selective attention processing, controls have a compensatory increase in prefrontal theta with age, while PWH have an aberrant decrease in prefrontal theta recruitment with age and instead exhibit an increase in parietal theta with age. The posterior parietal cortex has specifically been implicated as an essential node in the dorsal attention network, which is critical for top-down attentional control ([@fcaa015-B47]). Thus, this compensatory response may be in line with other functional neuroimaging studies of HIV, which have shown greater recruitment of brain reserve networks, specifically during higher attentional demands ([@fcaa015-B26]; [@fcaa015-B14]). Lastly, we also found reduced theta interference activity in PWH relative to controls, irrespective of age, in a more lateral right inferior parietal area that has also been implicated in attention function.

To better understand the clinical importance of these measures, we investigated how our neural findings were associated with HIV-related clinical measures, including global neuropsychological performance, duration of HIV infection, current CD4 count, CD4 nadir and current efavirenz-based antiretroviral therapy. This analysis showed that, in PWH, age remained the only variable that was associated with prefrontal activity above and beyond the other variables. Thus, the mechanism underlying the difference between PWH and controls in the prefrontal cortices remains unclear and definitely warrants further investigation. Greater left parietal activity, on the other hand, was associated with older age, longer time since HIV diagnosis and current efavirenz therapy. It is particularly interesting that each of these measures was independently related to parietal theta activity, controlling for all other variables. This means that, independent of age, the longer an individual has been diagnosed with HIV, the more their parietal activity is aberrant towards that seen in older PWH. This finding may indicate that neural damage associated with HIV is related to the amount of time HIV is present in the brain. Whether this may be better explained by the amount of time patients have a non-zero viral load, or instead continued neural damage despite virologic suppression due to HIV reservoirs in the brain is in need of further study. A pertinent negative finding in this context is that neuropsychological performance was not associated with theta interference activity in either of these two brain regions. Therefore, participants with HAND did not drive this difference, and the aberrant activity noted here may reflect pathologic brain ageing that is independent of HAND. While HIV-related premature ageing and HAND may be related to one another, our data suggest that the two are not mutually exclusive.

Interestingly, greater left parietal interference activity was also seen for PWH who are currently taking efavirenz. Efavirenz is well known to cause neurologic side effects including dizziness, mood changes and vivid dreams ([@fcaa015-B1]). Some studies have also linked efavirenz to neurocognitive deficits ([@fcaa015-B18]; [@fcaa015-B39]), although others have shown no neuropsychological differences ([@fcaa015-B19]). Our findings appear to link efavirenz to aberrant left parietal theta activity, which may be consistent with studies showing the neurotoxic effects of efavirenz ([@fcaa015-B5]; [@fcaa015-B17]). However, we did not find differences in global neuropsychological performance linked to current efavirenz therapy, which may indicate a neurotoxic process independent from neuropsychological performance, or at least beyond the functions tapped by our neuropsychological battery.

This study had several limitations. First, the exclusion of majority of participants from the full sample was due to current drug use, specifically cannabis use. While such exclusions help reduce confounds when examining the interaction between HIV and age, cannabis use is more prevalent in PWH ([@fcaa015-B44]) and therefore further study of this sub-population is important for generalizabilty. Along similar lines, our findings do not extend to individuals with moderate-to-severe depressive symptoms or other psychiatric co-morbidities, as such participants were excluded. Our findings also represent changes seen in virally suppressed PWH and may not extend to those with uncontrolled viraemia. Lastly, the neuropsychological battery administered was brief in nature, perhaps limiting variability in performance globally, and by individual cognitive domains.

In summary, we found that both behavioural and neural measures of selective attention function showed distinct relationships with ageing depending on serostatus. Our behavioural findings may support the notion of HIV-related premature ageing and be related to neuropsychological performance, while our neural findings may reflect HIV-related premature ageing that is independent of global neuropsychological performance. To our knowledge, this study is the largest functional neuroimaging study of HIV and the first to identify altered neural oscillatory activity in the context of HIV and ageing. These findings provide critical new data to aid in our understanding of the relationship between age, HIV and neuropsychological impairment, especially regarding the aberrant neural activity that underlies HIV-related neurologic impairment.
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cART =

:   combination antiretroviral therapy

HAND =

:   HIV-associated neurocognitive disorder

MEG =

:   magnetoencephalography

PWH =

:   persons with HIV
